Ocular Surface Changes in Glaucomatous Patients Treated With and Without Preservatives Beta-Blockers-Reference-Cited by-同舟云学术

Ocular Surface Changes in Glaucomatous Patients Treated With and Without Preservatives Beta-Blockers

Published:2014-08 Issue:6 Volume:30 Page:476-481
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Iester Michele¹,Telani Serena¹,Frezzotti Paolo²,Motolese Ilaria²,Figus Michele³,Fogagnolo Paolo⁴,Perdicchi Andrea⁵,

Affiliation:

1. Laboratorio Clinico Anatomo-Funzionale per la Diagnosi e il Trattamento del Glaucoma e Della Malattie Neurooftalmologiche, Clinica Oculistica, DiNOGMI, University of Genoa, Genoa, Italy.

2. Ophthalmology Unit, Department of Surgery, University of Siena, Siena, Italy.

3. Clinica Oculistica, University of Pisa, Pisa, Italy.

4. Eye Clinic, San Paolo Hospital, University of Milan, Milan, Italy.

5. Department of Ophthalmology, St. Andrea Hospital, University La Sapienza, Rome, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jop.2013.0216

Reference30 articles.

1. To preserve or not to preserve, is that the question?

2. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication

3. Symptoms and Signs of Tear Film Dysfunction in Glaucomatous Patients

4. Impact of glaucoma medication on ocular tissue

5. Adverse Effects of Topical Antiglaucoma Medication

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preservatives and ocular surface disease: A review;The Ocular Surface;2024-10

2. Exploring the Benefits of Preservative-Free Ophthalmic Solutions in the Management of Glaucoma: A Comprehensive Review;International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN);2024-06-30

3. COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT);Expert Opinion on Drug Safety;2023-09-06

4. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment;The Ocular Surface;2023-07

5. Topical glaucoma medications – Clinical implications for the ocular surface;The Ocular Surface;2022-10